Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use

In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this study is the evaluation of their effectiveness and tolerability in a real-life setting. A single-center observational s...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Borgo, Cosmo, Garattini, Silvia, Bortignon, Carolina, Carraro, Anna, Di Trento, Daniela, Gasperin, Andrea, Grimaldi, Alessandra, De Maria, Sara Giovanna, Corazza, Sara, Tieghi, Tiziana, Belvisi, Valeria, Kertusha, Blerta, De Masi, Margherita, D’Onofrio, Ombretta, Bagaglini, Gabriele, Bonanni, Gabriella, Zuccalà, Paola, Fabietti, Paolo, Tortellini, Eeva, Guardiani, Mariasilvia, Spagnoli, Alessandra, Marocco, Raffaella, Alunni Fegatelli, Danilo, Lichtner, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145588/
https://www.ncbi.nlm.nih.gov/pubmed/37113006
http://dx.doi.org/10.3390/v15041025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145588/
https://www.ncbi.nlm.nih.gov/pubmed/37113006
http://dx.doi.org/10.3390/v15041025

Ejemplares similares